Pfizer (PFE) Outperforms Broader Market: What You Need to Know

Company Performance - Pfizer (PFE) closed at $25.32, marking a +1.12% move from the prior day, outperforming the S&P 500 which gained 0.48% [1] - Over the past month, Pfizer's shares gained 7.24%, surpassing the Medical sector's gain of 2.8% and the S&P 500's gain of 5.13% [1] Upcoming Earnings Report - Pfizer is scheduled to release its earnings on August 5, 2025, with projected EPS of $0.57, indicating a 5.00% drop compared to the same quarter of the previous year [2] - The consensus estimate forecasts revenue to be $13.55 billion, reflecting a 2% growth compared to the corresponding quarter of the prior year [2] Annual Estimates - For the annual period, Zacks Consensus Estimates anticipate earnings of $3.06 per share and revenue of $63.25 billion, showing shifts of -1.61% and -0.6% from the last year [3] - Recent changes to analyst estimates for Pfizer indicate a favorable outlook on business health and profitability [3] Zacks Rank and Valuation - Pfizer currently has a Zacks Rank of 3 (Hold), with a 0.04% fall in the Zacks Consensus EPS estimate over the past month [5] - The company is trading at a Forward P/E ratio of 8.18, which is a discount compared to the industry average Forward P/E of 14.05 [5] PEG Ratio and Industry Context - Pfizer has a PEG ratio of 0.91, compared to the Large Cap Pharmaceuticals industry average PEG ratio of 1.24 [6] - The Large Cap Pharmaceuticals industry is currently ranked 158 in the Zacks Industry Rank, placing it in the bottom 37% of all industries [6][7]